Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs - Wikidata - wikimedia - TriplyDB

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

http://www.wikidata.org/entity/Q36915139

about

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Guidelines for the management of myeloproliferative neoplasms Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F New Therapeutic Approaches in Polycythemia Vera Clinical potential of pacritinib in the treatment of myelofibrosis Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.Management of polycythaemia vera: a critical review of current data.Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.Managing patients with myelofibrosis and low platelet counts.Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.Polycythemia Vera Management and Challenges in the Community Health Setting.Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Current and future treatment options for polycythemia vera.Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.Novel and emerging therapies for the treatment of polycythemia vera Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Polycythemia vera: current pharmacotherapy and future directions.Emerging drugs for polycythemia vera.Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis.The new landscape of therapy for myelofibrosis.Apoptosis deregulation in myeloproliferative neoplasms.Jak-2 positive myeloproliferative neoplasms.Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

P2860

Q26766319-C718B124-510F-4B03-80AF-CACCCFC3E2DB Q26778326-CE6253FB-BFBF-4285-A1A4-75B657C09B34 Q26779947-45FDF419-7D35-4D79-A850-9B2EB5003179 Q26795666-8487A1F3-A2BC-4E7D-AE80-CC700EE796EA Q26795677-B3770BAA-61AF-48E4-9D72-18D147075E78 Q26796450-92D6B59D-CC9E-4367-B4FC-53B537AC58AA Q26996258-D0480713-7553-4FF5-AC42-696FCB9BB37F Q28073296-6D68ECA1-09E4-4942-B505-CD0E153A9334 Q28078404-3520E166-0865-465E-BF6C-0744DD36597A Q30992878-F7125C51-B0B3-4D76-A5B5-3FAFCC8608DD Q31009757-769F480F-0306-480C-B433-A35DE133A8D7 Q33413428-90A5F2FC-4BAE-451E-A2C8-C5CAD070C7AB Q33417454-2B954637-6E72-4672-BD31-530AC581D8DF Q33420358-EC155AA0-38A8-4387-8C69-5FEF96FD94B8 Q33432406-C5D63912-3C92-41D3-B58C-05531CEFBB94 Q33434734-8E1FEF6E-79C8-4FBE-A199-7D7BB15EDDA3 Q33803036-4F1B4CFC-1EA3-43FF-88AD-63D08843051B Q34146512-40013A86-902A-4172-B7A6-96D8006F36B6 Q35188877-F225D6B5-E3E1-4407-B5B2-9F4988D8E8B1 Q35572748-B8E6F243-62A4-47B4-8D28-47E118F21DFD Q35938283-A71656F7-FE1E-408F-8997-A704EBFD8305 Q36266377-021A2297-C1DE-4923-976A-F46ABBC1B5E1 Q36708975-CED3C47B-4A4C-4C46-843B-6BEBA8ECC8B5 Q36708989-B218EE20-B8EC-4AF3-8936-65902454EE8D Q36782943-73684819-01B4-484A-8070-7D7C4D7379CF Q36907860-3B5606F1-C295-4310-9C49-B106AD6DB665 Q37069633-4938671B-D0FE-4CBE-B1E4-9197A435AD1F Q37255838-FB3CB397-00F5-4B27-8267-BE1D1BCE6898 Q37555790-6A2D1B02-E0FE-4ED1-8610-2FB915A996D4 Q37561170-D5D5A176-A211-4622-841D-D12460D22911 Q37631854-50DDFEFD-15D5-4A09-8E3A-59415B969336 Q37679175-3760E648-9EBE-4E75-ACB7-25515E227C4F Q37682689-6587FB35-3D1B-43D1-B12A-04AB61F4A29F Q38088262-BDF9B1B5-9D99-4FE2-ABBF-D1CF186FA0E0 Q38130749-DE59D820-9F7B-4BB0-8FFD-FD288EE11478 Q38143243-F9E75E81-178E-4145-BB83-3C9DEAAC60B9 Q38150261-37F590AD-8235-4C6D-A68B-E6D0FAC72CCD Q38184437-7B37FC9C-1D28-4611-8000-B8295B9B8EE4 Q38195778-5E09B274-F428-40EE-A66A-6BBC5DFB93A5 Q38207079-8D7047CB-3BA4-4314-9F35-01C6034EFE5F

P2860

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

http://www.wikidata.org/entity/Q36915139

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Myeloproliferative neoplasm (M ...... ystem among patients with MPNs

@en

type

label

Myeloproliferative neoplasm (M ...... ystem among patients with MPNs

@en

prefLabel

Myeloproliferative neoplasm (M ...... ystem among patients with MPNs

@en

P1433

Q36915139-E4A012D1-A02A-451A-BA05-D4A26FF2E5A2

P1476

Q36915139-A9F77625-BCEF-45F0-94BB-9DB416168526

P2093

Q36915139-05EA3265-70B3-4CFB-A1EC-DACA36C4DF0A

Q36915139-08240690-BE69-449E-B7E1-F71A10891AD1

Q36915139-0846DBAA-8DD2-4FBA-B6F7-C2F5DDDA841F

Q36915139-0A259FBA-8B46-400B-9CD1-08A0114F6299

Q36915139-0B039C57-225C-4F54-A972-FC59C81209BB

Q36915139-0B34451C-194C-4428-900D-E92B0C5EE2F5

Q36915139-0F001D70-FBDB-4BD1-8335-8270D5F357B6

Q36915139-0F81D3D5-9C1D-482A-9710-7B8931CABC0B

Q36915139-111CF8E3-9AD5-41BD-9E34-314531AAD6F6

Q36915139-1A8B3102-0F18-47F7-9F5E-F89E70735FD6

P2860

Q36915139-1C13A7A4-E723-467A-A104-AA731F5B4FDF

Q36915139-1D4EDC65-C387-4B92-9AE9-8E41CCA6283F

Q36915139-2CC2F05B-B5F8-4367-AF22-82F7E290435B

Q36915139-32E1272A-E92D-4DEF-8874-CFE3E328DD8C

Q36915139-48459D02-8059-440C-8EF5-09C9D4F561A6

Q36915139-7807E9B0-8192-454C-9322-137AF3B63697

Q36915139-96835A34-594B-4C31-9820-795DCC934A07

Q36915139-AA7449AA-312D-49E9-918F-549325E334D2

P304

Q36915139-4C721C3D-5701-44AF-966A-2973739E14E4

P31

Q36915139-EEE9CD7C-98CC-4675-A78E-4B6B51258C19

P356

Q36915139-BBF84062-CBA5-4CBD-913E-D42AFDF5275A

P407

Q36915139-BEF4B538-E106-40B5-95B6-AB7DBAF3B6B2

P433

Q36915139-564159E0-7A27-40D5-9F45-FCE314477151

P478

Q36915139-AD1B6B23-9F72-4181-975C-6D88CB8B44FE

P50

Q36915139-71F13C2C-AEBF-4123-B645-4B53587D7CCB

P577

Q36915139-E931A21E-AFC0-483A-9131-DF9B762A815F

P698

Q36915139-A6011DD1-E860-4D57-95AB-4569DC0DDB6E

P932

Q36915139-4D5C7759-910D-4289-9D17-A3A478ABD5D9

P356

JCO.2012.42.3863

P1433

Journal of Clinical Oncology

P1476

Myeloproliferative neoplasm (M ...... ystem among patients with MPNs

@en

P2093

Alessandro M Vannucchi

http://www.w3.org/2001/XMLSchema#string

Alessandro Rambaldi

http://www.w3.org/2001/XMLSchema#string

Amylou C Dueck

http://www.w3.org/2001/XMLSchema#string

Ana Kerguelen Fuentes

http://www.w3.org/2001/XMLSchema#string

Andreas Reiter

http://www.w3.org/2001/XMLSchema#string

Bjorn Andreasson

http://www.w3.org/2001/XMLSchema#string

Carlos Besses

http://www.w3.org/2001/XMLSchema#string

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Dana Ranta

http://www.w3.org/2001/XMLSchema#string

Deepti Radia

http://www.w3.org/2001/XMLSchema#string

P2860

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.

Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

P304

4098-4103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.42.3863

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23071245

http://www.w3.org/2001/XMLSchema#string

P932

4872304

http://www.w3.org/2001/XMLSchema#string